BENIGN OVARIAN LESION VS OVARIAN CANCER
ENDOMETRIOID CYST VS OVARIAN CANCER
DERMOID CYST VS OVARIAN CANCER
BENIGN EPITHELIAL TUMOR VS OVARIAN CANCER
OTHER BENIGN LESION VS OVARIAN CANCER
All
PM
M
All
PM
M
All
PM
M
All
PM
M
All
PM
M
SENSITIVITY [%]
ROMA
88
76.2
91.9
88
78.3
-
88
78.3
-
88
78.3
91.9
88
78.3
-
ROMA1
85.5
76.2
88.7
85.5
78.3
-
85.5
78.3
-
85.5
78.3
88.7
85.5
78.3
-
HE4
79.5
71.4
81.7
79.5
73.9
-
79.5
73.9
-
79.5
73.9
81.7
79.5
73.9
-
CA125
90.4
85.7
91.7
90.4
85.7
-
90.4
85.7
-
90.4
85.7
91.7
90.4
86.7
-
SPECIFICITY [%]
ROMA
88.5
91.6
80.6
83.3
85.7
-
95
94.1
-
85.3
100
72.7
91.2
89.5
-
ROMA1
95.4
96.8
91.7
96.3
95.8
-
100
100
-
91.9
100
86.4
93.4
92.3
-
HE4
87.8
89.5
83.3
92.6
90.9
-
95
94.1
-
81.1
100
90.9
89.5
87.2
-
CA125
72.5
71.6
75
45.8
54.2
-
90
88.2
-
70.6
85.7
59.9
79.2
71.7
-
PPV [%]
ROMA
83
66.7
88.7
94.8
85.7
-
98.6
94.7
-
93.4
100
90.2
94.8
83.3
-
ROMA1
92.2
84.2
87.5
98.6
94.7
-
100
100
-
95.9
100
94.6
95.9
85.7
-
HE4
80.4
60
89.1
97.1
89.5
-
98.5
94.4
-
90.4
100
96.1
92.9
77.3
-
CA125
67.6
40
85.9
85.2
61.9
-
97.4
90.9
-
88.2
90.9
85.9
88.2
64.5
-
NPV [%]
ROMA
92.1
94.6
85.3
66.6
78.3
-
65.5
76.2
-
74.4
66.6
76.2
81.5
82.9
-
ROMA1
91.2
94.8
82.5
74.3
82.1
-
76.5
77.3
-
85
75
73.1
83.3
87.8
-
HE4
87.1
93.4
73.2
59.5
78.6
-
52.7
72.7
-
63.8
71.4
64.5
71.7
85
-
CA125
92.2
95.8
84.4
57.9
78.5
-
69.2
83.3
-
75
80
72.2
82.6
90.3
-
All – PM+M; PM – Premenopause; M – Postmenopause ; ROMA 1 – risk stratification based on cutoff points determined by authors
Table 3:
Sensitivity, specificity, PPV, and NPV of CA125, HE4, and ROMA for ovarian cancer screening in patients with a pelvic mass.
